CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CEO Xingjuan Chao sold 39,540 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $24.61, for a total transaction of $973,079.40. Following the completion of the sale, the chief executive officer owned 767,191 shares of the company’s stock, valued at approximately $18,880,570.51. The trade was a 4.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Xingjuan Chao also recently made the following trade(s):
- On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $145,753.36.
- On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $786,317.45.
- On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $54,975.00.
- On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
- On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.33, for a total value of $714,870.00.
CeriBell Stock Up 0.6%
Shares of CeriBell stock traded up $0.15 during trading on Friday, hitting $24.72. 220,005 shares of the stock traded hands, compared to its average volume of 343,502. The stock has a market cap of $948.70 million, a P/E ratio of -14.05 and a beta of 0.95. The company has a fifty day moving average price of $20.57 and a two-hundred day moving average price of $19.46. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 28th. Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Raymond James Financial reissued a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday. Finally, BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.40.
View Our Latest Research Report on CBLL
Institutional Investors Weigh In On CeriBell
Several hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its position in shares of CeriBell by 409.5% during the 2nd quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock worth $143,000 after purchasing an additional 5,909 shares during the last quarter. Wellington Management Group LLP increased its position in CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after buying an additional 4,572 shares during the period. Formula Growth Ltd. bought a new position in CeriBell in the 2nd quarter worth approximately $603,000. Bank of America Corp DE acquired a new position in shares of CeriBell during the second quarter worth approximately $4,619,000. Finally, PDT Partners LLC bought a new stake in shares of CeriBell in the second quarter valued at approximately $1,026,000.
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
- Five stocks we like better than CeriBell
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
